
Joerg Buddenkotte

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3541827/publications.pdf Version: 2024-02-01



LOEPC RUDDENKOTTE

#	Article	IF	CITATIONS
1	Role of non-coding RNAs in the progression and resistance of cutaneous malignancies and autoimmune diseases. Seminars in Cancer Biology, 2022, 83, 208-226.	9.6	16
2	Molecular pathogenesis of Cutaneous T cell Lymphoma: Role of chemokines, cytokines, and dysregulated signaling pathways. Seminars in Cancer Biology, 2022, 86, 382-399.	9.6	21
3	Neuroimmune communication regulating pruritus in atopic dermatitis. Journal of Allergy and Clinical Immunology, 2022, 149, 1875-1898.	2.9	49
4	Epigenetic regulation of CXCR4 signaling in cancer pathogenesis and progression. Seminars in Cancer Biology, 2022, 86, 697-708.	9.6	15
5	Recalcitrant erythrodermic ichthyosis with atopic dermatitis successfully treated with Dupilumab in combination with Guselkumab. Skin Health and Disease, 2022, 2, .	1.5	7
6	The PLAUR signaling promotes chronic pruritus. FASEB Journal, 2022, 36, .	0.5	10
7	Neurokinin 1 Receptor Antagonists for Pruritus. Drugs, 2021, 81, 621-634.	10.9	6
8	Interleukinâ€31: The "itchy―cytokine in inflammation and therapy. Allergy: European Journal of Allergy and Clinical Immunology, 2021, 76, 2982-2997.	5.7	95
9	Treatment and molecular profiling of acrodermatitis continua of Hallopeau during pregnancy using targeted therapy. JAAD Case Reports, 2021, 16, 164-167.	0.8	1
10	Dysregulated Phosphorylation of p53, Autophagy and Stemness Attributes the Mutant p53 Harboring Colon Cancer Cells Impaired Sensitivity to Oxaliplatin. Frontiers in Oncology, 2020, 10, 1744.	2.8	14
11	Protease-Activated Receptor-2 Regulates Neuro-Epidermal Communication in Atopic Dermatitis. Frontiers in Immunology, 2020, 11, 1740.	4.8	46
12	Exosomes: Emerging Diagnostic and Therapeutic Targets in Cutaneous Diseases. International Journal of Molecular Sciences, 2020, 21, 9264.	4.1	18
13	Role of neuroimmune circuits and pruritus in psoriasis. Experimental Dermatology, 2020, 29, 414-426.	2.9	39
14	Interleukinâ€4 and interleukinâ€13 evoke scratching behaviour in mice. Experimental Dermatology, 2019, 28, 1501-1504.	2.9	76
15	Protein Expression Profiling Identifies Key Proteins and Pathways Involved in Growth Inhibitory Effects Exerted by Guggulsterone in Human Colorectal Cancer Cells. Cancers, 2019, 11, 1478.	3.7	16
16	Role of SNAREs in Atopic Dermatitis–Related Cytokine Secretion and Skin-Nerve Communication. Journal of Investigative Dermatology, 2019, 139, 2324-2333.	0.7	18
17	Understanding the Burden of Atopic Dermatitis in Africa and the Middle East. Dermatology and Therapy, 2019, 9, 223-241.	3.0	30
18	New mechanism underlying IL-31–induced atopic dermatitis. Journal of Allergy and Clinical Immunology, 2018, 141, 1677-1689.e8.	2.9	131

JOERG BUDDENKOTTE

#	Article	IF	CITATIONS
19	Role of mast cells and basophils in pruritus. Immunological Reviews, 2018, 282, 248-264.	6.0	58
20	Recent advances in understanding and managing rosacea. F1000Research, 2018, 7, 1885.	1.6	110
21	The pruritus- and TH2-associated cytokine IL-31 promotes growth of sensory nerves. Journal of Allergy and Clinical Immunology, 2016, 138, 500-508.e24.	2.9	201
22	Molecular and Morphological Characterization of Inflammatory Infiltrate in Rosacea Reveals Activation of Th1/Th17 Pathways. Journal of Investigative Dermatology, 2015, 135, 2198-2208.	0.7	193
23	A sensory neuron–expressed IL-31 receptor mediates TÂhelper cell–dependent itch: Involvement of TRPV1 andÂTRPA1. Journal of Allergy and Clinical Immunology, 2014, 133, 448-460.e7.	2.9	556
24	Neural peptidase endothelin-converting enzyme 1 regulates endothelin 1–induced pruritus. Journal of Clinical Investigation, 2014, 124, 2683-2695.	8.2	81
25	Distribution and Expression of Non-Neuronal Transient Receptor Potential (TRPV) Ion Channels in Rosacea. Journal of Investigative Dermatology, 2012, 132, 1253-1262.	0.7	182
26	Evaluation and management of a patient with chronic pruritus. Journal of Allergy and Clinical Immunology, 2012, 130, 1015-1016.e7.	2.9	19
27	Clinical, Cellular, and Molecular Aspects in the Pathophysiology of Rosacea. Journal of Investigative Dermatology Symposium Proceedings, 2011, 15, 2-11.	0.8	227
28	Management of Itch in Atopic Dermatitis. Seminars in Cutaneous Medicine and Surgery, 2011, 30, 71-86.	1.6	121
29	Neurovascular and Neuroimmune Aspects in the Pathophysiology of Rosacea. Journal of Investigative Dermatology Symposium Proceedings, 2011, 15, 53-62.	0.8	215
30	Pathophysiology and therapy of pruritus in allergic and atopic diseases. Allergy: European Journal of Allergy and Clinical Immunology, 2010, 65, 805-821.	5.7	112
31	Pituitary Adenylate Cyclase Activating Polypeptide. American Journal of Pathology, 2010, 177, 2563-2575.	3.8	64
32	Functional Characterization and Expression Analysis of the Proteinase-Activated Receptor-2 in Human Cutaneous Mast Cells. Journal of Investigative Dermatology, 2006, 126, 746-755.	0.7	97
33	Agonists of Proteinase-Activated Receptor-2 Stimulate Upregulation of Intercellular Cell Adhesion Molecule-1 in Primary Human Keratinocytes via Activation of NF-kappa B. Journal of Investigative Dermatology, 2005, 124, 38-45.	0.7	115
34	Proteinase-Activated Receptors: Transducers of Proteinase-Mediated Signaling in Inflammation and Immune Response. Endocrine Reviews, 2005, 26, 1-43.	20.1	469
35	Agonists of Proteinase-Activated Receptor 2 Induce Cytokine Release and Activation of Nuclear Transcription Factor ήB in Human Dermal Microvascular Endothelial Cells. Journal of Investigative Dermatology, 2002, 118, 380-385.	0.7	115